New combo therapy aims to shrink spleens in Hard-to-Treat myelofibrosis
NCT ID NCT06397313
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests an experimental drug called RVU120 in adults with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. Participants will receive RVU120 alone or together with the standard drug ruxolitinib. The main goal is to see if the treatment can shrink the spleen by at least 35% after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"
RECRUITINGCatania, Italy
Contact
Contact
-
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
RECRUITINGBrescia, Italy
Contact
Contact
-
Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz
RECRUITINGGdansk, Poland
Contact
Contact
-
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
RECRUITINGMilan, Italy
Contact
Contact
-
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.
RECRUITINGMeldola, Italy
Contact
Contact
-
Lux Med Onkologia Sp. z o.o.
RECRUITINGWarsaw, Poland
Contact
Contact
-
M2M Med. Sp. z o.o. Sp. j.
RECRUITINGChorzów, Poland
Contact
Contact
-
Policlinico Sant'Orsola-Malpighi
RECRUITINGBologna, Italy
Contact
Contact
-
Pratia Hematologia Sp. z o.o.
RECRUITINGKatowice, Poland
Contact
Contact
-
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
RECRUITINGLublin, Poland
Contact
Contact
-
Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
RECRUITINGKrakow, Poland
Contact
Contact
-
Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.
COMPLETEDZielona Góra, Poland
-
Szpital Uniwersytecki nr 2 im. dr Jana Biziela
RECRUITINGBydgoszcz, Poland
Contact
Contact
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
RECRUITINGWroclaw, Poland
Contact
Contact
-
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
RECRUITINGBiała Podlaska, Poland
Contact
Contact
-
Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
RECRUITINGTorun, Poland
Contact
Contact
-
Wojskowy Instytut Medyczny Państwowy Instytut Badawczy
RECRUITINGWarsaw, Poland
Contact
Contact
-
Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej
COMPLETEDKielce, Poland
Conditions
Explore the condition pages connected to this study.